<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Med Sci</journal-id><journal-id journal-id-type="publisher-id">AMS</journal-id><journal-title-group><journal-title>Archives of Medical Science : AMS</journal-title></journal-title-group><issn pub-type="ppub">1734-1922</issn><issn pub-type="epub">1896-9151</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22371748</article-id><article-id pub-id-type="pmc">3281341</article-id><article-id pub-id-type="publisher-id">14648</article-id><article-id pub-id-type="doi">10.5114/aoms.2010.13896</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Treatment with double dose of omeprazole increases &#x003b2;-endorphin plasma level in patients with coronary artery disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Budzy&#x00144;ski</surname><given-names>Jacek</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pulkowski</surname><given-names>Grzegorz</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>K&#x00142;opocka</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Augusty&#x00144;ska</surname><given-names>Beata</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sinkiewicz</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Suppan</surname><given-names>Karol</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fabisiak</surname><given-names>Jacek</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Majer</surname><given-names>Marcin</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>&#x0015a;wi&#x00105;tkowski</surname><given-names>Maciej</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Gastroenterology, Vascular Diseases and Internal Medicine, Nicolaus Copernicus University in Toru&#x00144;, Collegium Medicum in Bydgoszcz, Poland</aff><aff id="aff2"><label>2</label>Clinical Ward of Vascular Diseases and Internal Medicine, Doctor Jan Biziel University Hospital no. 2, Bydgoszcz, Poland</aff><aff id="aff3"><label>3</label>Department of Psychiatric Nursing, Nicolaus Copernicus University in Toru&#x00144;, Collegium Medicum in Bydgoszcz, Poland</aff><aff id="aff4"><label>4</label>The Outpatient Phoniatrics Department, Doctor Jan Biziel University Hospital no. 2 in Bydgoszcz, Poland</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Jacek Budzy&#x00144;ski, MD, PhD, Department of Gastroenterology, Vascular Diseases and Internal Medicine, Nicolaus Copernicus University in Toru&#x00144;, Collegium Medicum in Bydgoszcz, Ujejskiego 75 Street, 85-168 Bydgoszcz, Poland, Fax: +48 52 371 49 12. E-mail: <email xlink:href="budz@cps.pl">budz@cps.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>4</month><year>2010</year></pub-date><pub-date pub-type="ppub"><day>30</day><month>4</month><year>2010</year></pub-date><volume>6</volume><issue>2</issue><fpage>201</fpage><lpage>207</lpage><history><date date-type="received"><day>05</day><month>1</month><year>2009</year></date><date date-type="rev-recd"><day>17</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2010 Termedia &#x00026; Banach</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Introduction</title><p>The proton pump inhibitor empirical trial, besides the analysis of symptoms, is the main method in the diagnosis of gastro-oesophageal reflux disease-related chest pain. &#x003b2;-Endorphin acts as an endogenous analgesia system. The aim of the study was verify whether &#x003b2;-endorphin plasma level is affected by omeprazole administration and influences the severity of anginal symptoms and outcome of the &#x0201c;omeprazole test&#x0201d; in patients with coronary artery disease (CAD) and chest pain of suspected non-cardiac origin.</p></sec><sec id="st2"><title>Material and methods</title><p>Omeprazole was administered to 48 patients with CAD in a randomized, placebo-controlled, crossover study design. At the beginning of the study, and again after the 14-day omeprazole and placebo treatment, the &#x003b2;-endorphin plasma concentration was determined.</p></sec><sec id="st3"><title>Results</title><p>The level of plasma &#x003b2;-endorphin after the administration of omeprazole was significantly greater than at the start of the study and following the placebo. Responders to omeprazole had an average lower &#x003b2;-endorphin plasma concentration than subjects who failed to respond to this therapy. Subjects with symptoms in class III (according to the Canadian Cardiovascular Society classification) after omeprazole administration had a greater &#x003b2;-endorphin plasma level than subjects in class II for anginal symptom severity.</p></sec><sec id="st4"><title>Conclusions</title><p>Fourteen-day therapy with a double omeprazole dose significantly increases the &#x003b2;-endorphin plasma concentration in patients with CAD. Circulating &#x003b2;-endorphin does not seem to be involved in the mechanism for the &#x0201c;omeprazole test&#x0201d; outcome, although an individually different effect on pain threshold cannot be excluded.</p></sec></abstract><kwd-group><kwd>&#x003b2;-endorphin</kwd><kwd>omeprazole test</kwd><kwd>chest pain</kwd><kwd>coronary artery disease</kwd></kwd-group></article-meta></front><body><sec id="S0001"><title>Introduction</title><p>Chest pain is one of the most common symptoms in health care. The mean annual prevalence of angina-like retrosternal chest pain of non-cardiac origin (non-cardiac chest pain, NCCP) in the general population is approximately 25% [<xref ref-type="bibr" rid="CIT0001">1</xref>, <xref ref-type="bibr" rid="CIT0002">2</xref>]. The most frequent cause of NCCP is gastro- oesophageal reflux disease (GORD), which frequently coexists with coronary artery disease (CAD) [<xref ref-type="bibr" rid="CIT0003">3</xref>]. GORD-related chest pain may be indistinguishable from ischaemic cardiac pain [<xref ref-type="bibr" rid="CIT0001">1</xref>&#x02013;<xref ref-type="bibr" rid="CIT0003">3</xref>]. After excluding its cardiac source, empirical therapy with a double or triple standard dose of proton pump inhibitor is recommended as an initial diagnostic approach [<xref ref-type="bibr" rid="CIT0001">1</xref>, <xref ref-type="bibr" rid="CIT0002">2</xref>, <xref ref-type="bibr" rid="CIT0004">4</xref>&#x02013;<xref ref-type="bibr" rid="CIT0006">6</xref>]. The results of our investigations showed that 14-day therapy with a double dose of rabeprazole (open-label trial) [<xref ref-type="bibr" rid="CIT0003">3</xref>] or omeprazole (randomized, placebo controlled cross-over trial) [<xref ref-type="bibr" rid="CIT0007">7</xref>] leads to a decrease in the number of total chest pain episodes and in some electrocardiographic signs of myocardial ischaemia in patients with stable angina pectoris and CAD. The pathomechanism of symptom improvement after therapy with proton pump inhibitor is mostly explained by a decrease in oesophageal mucosa injury, diminished chemo- and mechanoreceptor stimulation, as well as reduction in secondary motor reaction with hypertensive contractions of the circular and longitudinal oesophageal muscles [<xref ref-type="bibr" rid="CIT0008">8</xref>, <xref ref-type="bibr" rid="CIT0009">9</xref>]. In about half of patients with CAD, related to gastric acid secretion inhibition, decrease of stimulus for the cardio-oesophageal reflex and the prevention of reflexive reduction in myocardial perfusion should also be taken into consideration [<xref ref-type="bibr" rid="CIT0003">3</xref>, <xref ref-type="bibr" rid="CIT0007">7</xref>, <xref ref-type="bibr" rid="CIT0010">10</xref>, <xref ref-type="bibr" rid="CIT0011">11</xref>]. Moreover, because of the proven role of changes in the central and peripheral pain threshold in pathogenesis of non-cardiac chest pain [<xref ref-type="bibr" rid="CIT0001">1</xref>, <xref ref-type="bibr" rid="CIT0002">2</xref>, <xref ref-type="bibr" rid="CIT0008">8</xref>, <xref ref-type="bibr" rid="CIT0009">9</xref>], mediators of the brain-gut axis might also have potential importance in the outcome of empirical therapy with proton pump inhibitor. Recently, Dickman <italic>et al</italic>. [<xref ref-type="bibr" rid="CIT0012">12</xref>] reported that acupuncture is more effective than the addition of a second proton pump inhibitor dose in therapy of heartburn in patients who failed to respond to a single dose. Because it is accepted that acupuncture works through modulation of endogenous opioids&#x02019; release, the results of this study suggested involvement of the opioid system in control of GORD-related symptoms. Opioids, as the &#x0201c;endogenous analgesia system&#x0201d;, play a role in mechanisms of somatic and visceral pain perception, affect behavioural processes, such as learning and memory [<xref ref-type="bibr" rid="CIT0013">13</xref>], modulate the pain threshold and mood state in patients with CAD [<xref ref-type="bibr" rid="CIT0014">14</xref>&#x02013;<xref ref-type="bibr" rid="CIT0019">19</xref>] and duodenal ulcer disease [<xref ref-type="bibr" rid="CIT0020">20</xref>], and regulate blood pressure, through the endorphin/encephalin balance [<xref ref-type="bibr" rid="CIT0013">13</xref>, <xref ref-type="bibr" rid="CIT0021">21</xref>].</p><p>Because the relationships between &#x003b2;-endorphin plasma level and outcome of therapy with proton pump inhibitor in patients with CAD had not been studied, we estimated the changes in &#x003b2;-endorphin plasma level after omeprazole and placebo administration. The influence of observed changes in this opioid plasma concentration on angina symptoms severity was also assessed.</p></sec><sec sec-type="materials|methods" id="S0002"><title>Material and methods</title><p>We studied 48 patients with obstructive CAD, proven through coronarography: 11 females (23%) and 37 males (77%), recruited from a cardiology outpatient clinic. They suffered from stable, recurrent, angina-like chest pain, but failed to respond to standard anti-anginal therapy. For this reason overlapping of its non-cardiac sources was suspected. The mean age of the study population was 59.6 &#x000b1;7.2 years. The remaining demographic and clinical data of subjects, stratified by gender, are presented in <xref ref-type="table" rid="T0001">Table I</xref>. All individuals included in the experiment participated in all phases of the study and completed it. None discontinued therapy.
</p><table-wrap id="T0001" position="float"><label>Table I</label><caption><p>Demographic and clinical data of studied subjects with CAD (<italic>n</italic> = 48)</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Feature</th><th align="center" rowspan="1" colspan="1">Mean &#x000b1;SD or <italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Females (<italic>n</italic> = 11, 23%)</th><th align="center" rowspan="1" colspan="1">Males (<italic>n</italic> = 37, 77%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age [years]</td><td align="center" rowspan="1" colspan="1">59.6 &#x000b1;7.2</td><td align="center" rowspan="1" colspan="1">58.8 &#x000b1;7.3</td><td align="center" rowspan="1" colspan="1">62.9 &#x000b1;6.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of anginal symptoms per week</td><td align="center" rowspan="1" colspan="1">12.9 &#x000b1;7.9 (median = 8; range = 5&#x02013;35)</td><td align="center" rowspan="1" colspan="1">13.4 &#x000b1;5.9 (median = 12; range = 6&#x02013;26)</td><td align="center" rowspan="1" colspan="1">12.8 &#x000b1;8.5 (median = 10; range = 6-50)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of patients with anginal symptoms severity graded according to CCS classification</td><td align="center" rowspan="1" colspan="1">class II &#x02013; 36 (75%) class III &#x02013; 12 (25%)</td><td align="center" rowspan="1" colspan="1">class II &#x02013; 9 (82%) class III &#x02013; 2 (18%)</td><td align="center" rowspan="1" colspan="1">class II &#x02013; 27 (73%) class III &#x02013; 10 (27%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidaemia</td><td align="center" rowspan="1" colspan="1">44 (92%)</td><td align="center" rowspan="1" colspan="1">11 (100%)</td><td align="center" rowspan="1" colspan="1">33 (89%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Concentration of total cholesterol [mg/dl]</td><td align="center" rowspan="1" colspan="1">232.7 &#x000b1;43.8</td><td align="center" rowspan="1" colspan="1">202.1 &#x000b1;41.2</td><td align="center" rowspan="1" colspan="1">184.7 &#x000b1;25.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Concentration of LDL cholesterol [mg/dl]</td><td align="center" rowspan="1" colspan="1">179.7 &#x000b1;60.1</td><td align="center" rowspan="1" colspan="1">121.3 &#x000b1;36.8</td><td align="center" rowspan="1" colspan="1">95.3 &#x000b1;26.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Concentration of HDL cholesterol [mg/dl]</td><td align="center" rowspan="1" colspan="1">49.5 &#x000b1;12.6</td><td align="center" rowspan="1" colspan="1">49.0 &#x000b1;12.8</td><td align="center" rowspan="1" colspan="1">61.2 &#x000b1;17.6<xref ref-type="fn" rid="TF0001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Concentration of triglycerides [mg/dl]</td><td align="center" rowspan="1" colspan="1">234.7 &#x000b1;111.4</td><td align="center" rowspan="1" colspan="1">187.1 &#x000b1;111.5</td><td align="center" rowspan="1" colspan="1">136.3 &#x000b1;63.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">24 (51%)</td><td align="center" rowspan="1" colspan="1">1 (9%)</td><td align="center" rowspan="1" colspan="1">23 (90%)<xref ref-type="fn" rid="TF0001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">14 (27%)</td><td align="center" rowspan="1" colspan="1">4 (36%)</td><td align="center" rowspan="1" colspan="1">10 (27%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">12 (25%)</td><td align="center" rowspan="1" colspan="1">3 (27%)</td><td align="center" rowspan="1" colspan="1">9 (24%)</td></tr><tr><td align="left" rowspan="1" colspan="1">History of myocardial infarction</td><td align="center" rowspan="1" colspan="1">30 (63%)</td><td align="center" rowspan="1" colspan="1">6 (54%)</td><td align="center" rowspan="1" colspan="1">23 (65%)</td></tr><tr><td align="left" rowspan="1" colspan="1">History of PCI</td><td align="center" rowspan="1" colspan="1">16 (34%)</td><td align="center" rowspan="1" colspan="1">3 (27%)</td><td align="center" rowspan="1" colspan="1">13 (35%)</td></tr><tr><td align="left" rowspan="1" colspan="1">History of CABG</td><td align="center" rowspan="1" colspan="1">7 (15%)</td><td align="center" rowspan="1" colspan="1">2 (18%)</td><td align="center" rowspan="1" colspan="1">5 (13%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction in echocardiography [%]</td><td align="center" rowspan="1" colspan="1">54.3 &#x000b1;9.2</td><td align="center" rowspan="1" colspan="1">54.5 &#x000b1;9.9</td><td align="center" rowspan="1" colspan="1">54.2 &#x000b1;7.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin administration</td><td align="center" rowspan="1" colspan="1">47 (98%)</td><td align="center" rowspan="1" colspan="1">11 (100%)</td><td align="center" rowspan="1" colspan="1">36 (97%)</td></tr><tr><td align="left" rowspan="1" colspan="1">-Blockers administration</td><td align="center" rowspan="1" colspan="1">44 (92%)</td><td align="center" rowspan="1" colspan="1">9 (82%)</td><td align="center" rowspan="1" colspan="1">35 (95%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium-blockers administration</td><td align="center" rowspan="1" colspan="1">13 (28%)</td><td align="center" rowspan="1" colspan="1">3 (27%)</td><td align="center" rowspan="1" colspan="1">10 (27%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEI administration</td><td align="center" rowspan="1" colspan="1">39 (81%)</td><td align="center" rowspan="1" colspan="1">8 (72%)</td><td align="center" rowspan="1" colspan="1">31 (83%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of nitroglycerine tablets taken per week</td><td align="center" rowspan="1" colspan="1">3.9 &#x000b1;4.3 (median = 3; range 1&#x02013;20)</td><td align="center" rowspan="1" colspan="1">4.6 &#x000b1;4.9 (median = 3; range = 0&#x02013;15)</td><td align="center" rowspan="1" colspan="1">3.6 &#x000b1;4.1 (median = 3; range = 0&#x02013;20)</td></tr><tr><td align="left" rowspan="1" colspan="1">Long-acting nitrates administration</td><td align="center" rowspan="1" colspan="1">22 (45%)</td><td align="center" rowspan="1" colspan="1">6 (55%)</td><td align="center" rowspan="1" colspan="1">16 (43%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin administration</td><td align="center" rowspan="1" colspan="1">45 (100%)</td><td align="center" rowspan="1" colspan="1">11 (100%)</td><td align="center" rowspan="1" colspan="1">34 (92%)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI [kg/m<sup><sup>2</sup></sup>]</td><td align="center" rowspan="1" colspan="1">28.3 &#x000b1;3.7</td><td align="center" rowspan="1" colspan="1">26.9 &#x000b1;4.7</td><td align="center" rowspan="1" colspan="1">28.7 &#x000b1;3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">WHR</td><td align="center" rowspan="1" colspan="1">0.93 &#x000b1;0.07</td><td align="center" rowspan="1" colspan="1">0.85 &#x000b1;0.06</td><td align="center" rowspan="1" colspan="1">0.96 &#x000b1;0.06<xref ref-type="fn" rid="TF0001">*</xref></td></tr></tbody></table><table-wrap-foot><fn><p>CAD &#x02013; coronary artery disease, PCI &#x02013; percutaneous coronary intervention, CABG &#x02013; coronary artery bypass graft, BMI &#x02013; body mass index, WHR &#x02013; waist to hip (circumferences) ratio, ACEI &#x02013; angiotensin-converting enzyme inhibitor,</p></fn><fn id="TF0001"><p><sup>*</sup><italic>p &#x0003c;0.05 for differences between females and males</italic></p></fn></table-wrap-foot></table-wrap><p>The investigation was performed according to the double-blind, crossover, randomized, placebo-controlled design, so patients acted as their own controls. With all the patients, an interview, physical examination, blood sampling for biochemical determination and the treadmill stress test according to the Bruce protocol (Schiller, Switzerland) were carried out. After the baseline examination, each patient was assigned a consecutive drug kit, according to the sequence of his or her participation in the investigation. Each kit consisted of two boxes with 28 identical-looking capsules containing 20 mg of omeprazole or the placebo (filling materials without omeprazole like in capsules with omeprazole). Randomization was carried out at the stage of preparing the kits. In the first investigation phase, patients were asked to take capsules of omeprazole or the placebo for 14 days, and in the second phase patients were crossed over to the other arm (omeprazole &#x02192; placebo or placebo &#x02192; omeprazole). This treatment was recommended as being given in addition to therapy up to that point. The doses of this medication did not change for the entire period of the investigation. Moreover, the participants did not change their smoking and alcohol drinking habits or lifestyle. Patients were only permitted to take short-acting alkalis and nitroglycerine. Following each of the two phases of the investigation, all study procedures, i.e. the interview, physical examination, blood sampling and treadmill stress test, were repeated.</p><sec id="S20007"><title>Determination of &#x003b2;-endorphin plasma concentration</title><p>Blood samples were collected at approximately 7:15 am, after 15 min of rest, into Lavender Vacutaner tubes containing EDTA, and gently rocked immediately after collection to ensure anticoagulation. The samples were then centrifuged for 15 min at 4&#x000b0;C to collect the plasma, which was then kept at &#x02212;80&#x000b0;C. &#x003b2;-Endorphin estimations in the serum were carried out according to the producer's instructions by enzyme-linked immunosorbent assay (ELISA) (MD Biosciences, Z&#x000fc;rich, Switzerland). The test sensitivity was 0.18 pg/ml, intra-assay variation &#x0003c; 5%, inter-assay variation &#x0003c; 14%.</p></sec><sec id="S20008"><title>Statistical analysis</title><p>Statistical analysis was conducted using a licensed version of the statistical software STATISTICA PL 5.0 for Windows. The results are presented as the mean &#x000b1; standard deviation (SD) or <italic>n</italic>, %. The statistical significance of differences between females and males (<xref ref-type="table" rid="T0001">Table I</xref>) was checked using unpaired Student's <italic>t</italic>-test and Fisher's exact test. The effect of respective interventions on the &#x003b2;-endorphin level was estimated using ANOVA with three repetitions and the Scheffe post hoc test, so all subjects acted as their own controls. Rank Spearman correlations between the &#x003b2;-endorphin plasma concentration and the values of the treadmill stress test parameters were tested.</p></sec><sec id="S20009"><title>Ethics</title><p>The study protocol was approved by the local Bioethics Committee of Nicolaus Copernicus University in Toru&#x00144; and Collegium Medicum in Bydgoszcz, Poland. All subjects gave their informed consent prior to the start of enrolment procedures. All procedures have been conducted in compliance with the Declaration of Helsinki.</p></sec></sec><sec id="S0003"><title>Results</title><p>The plasma &#x003b2;-endorphin concentration after 2-week therapy with omeprazole was significantly greater than at the beginning of the study and after the administration of the placebo (<xref ref-type="fig" rid="F0001">Figure 1</xref>). Response to omeprazole, defined as decrease in chest pain severity after proton pump inhibitor administration more than by half, had no significant effect on changes in &#x003b2;-endorphin plasma level during the investigation (interaction with the study phase) (<xref ref-type="fig" rid="F0002">Figure 2</xref>). However, patients who reported a greater than 50% reduction in the number of chest pain episodes (responders) following treatment with omeprazole (<italic>n</italic> = 17/48, 35%) had a significantly lower average &#x003b2;-endorphin plasma concentration during the whole study period than the remaining subjects (ANOVA: main effect of clinical outcome; <italic>F</italic> = 4.9, <italic>p</italic> = 0.037) (<xref ref-type="fig" rid="F0003">Figure 3</xref>).</p><fig id="F0001" position="float"><label>Figure 1</label><caption><p>&#x003b2;-Endorphin plasma level at the study beginning, and after omeprazole and placebo administration. ANOVA, <italic>F</italic> = 36.0, <italic>p</italic> &#x0003c; 0.0001</p></caption><graphic xlink:href="AMS-6-14648-g001"/></fig><fig id="F0002" position="float"><label>Figure 2</label><caption><p>Differences in &#x003b2;-endorphin plasma level at the study start and after following study phases in patients who responded or not to the double dose of omeprazole. &#x0201c;Responders&#x0201d; were defined as subjects who reported decrease in chest pain frequency after omeprazole administration by more than 50%, and &#x0201c;non-responders&#x0201d; were defined as individuals with less or lack of improvement. Interaction between study phase and response to kind of treatment, ANOVA with three repetitions: <italic>F</italic> = 2,2,06, <italic>p</italic> = 0.14</p></caption><graphic xlink:href="AMS-6-14648-g002"/></fig><fig id="F0003" position="float"><label>Figure 3</label><caption><p>The main effect of kind of treatment clinical outcome on average &#x003b2;-endorphin plasma concentration during all three study phases. ANOVA, <italic>F</italic> = 4.9, <italic>p</italic> = 0.037</p></caption><graphic xlink:href="AMS-6-14648-g003"/></fig><p>The changes in the &#x003b2;-endorphin plasma level after omeprazole therapy were related to the severity of anginal symptoms before the patient's involvement in the study, both in one- and in two-factorial analysis (ANOVA: <italic>F</italic> = 4.72, <italic>p</italic> = 0.013) (<xref ref-type="fig" rid="F0004">Figure 4</xref>). Subjects with symptoms in class III, according to the Canadian Cardiovascular Society (CCS) classification (<italic>n</italic> = 12/48), had a significantly greater plasma level of &#x003b2;-endorphin after 2-week omeprazole administration than subjects (<italic>n</italic> = 36/48) with class II anginal symptom severity (1246.3&#x000b1;778.0 vs. 643.6 &#x000b1;525.5 pg/ml, <italic>p</italic> = 0.004). The remaining clinical factors, such as randomization when taking omeprazole in the first study phase, gender, age, hypertension, diabetes, dyslipidaemia, smoking, alcohol drinking, and the kind of CAD treatment, had no significant effect on &#x003b2;-endorphin plasma concentration. We did not find any statistically significant relationships between the &#x003b2;-endorphin plasma level and the course of the treadmill stress test, either at the start of the study or after therapy with omeprazole or the placebo.</p><fig id="F0004" position="float"><label>Figure 4</label><caption><p>Differences in &#x003b2;-endorphin plasma level in relation to anginal symptoms severity before the patient's involvement in the study. ANOVA with three repetitions: <italic>F</italic> = 4.8, <italic>p</italic> = 0.013</p></caption><graphic xlink:href="AMS-6-14648-g004"/></fig></sec><sec id="S0004"><title>Discussion</title><p>In our study we found an enormous increase of &#x003b2;-endorphin plasma concentration after 14 days&#x02019; administration of a double dose of omeprazole (<xref ref-type="fig" rid="F0001">Figure 1</xref>). To our knowledge, this is the first report showing, in a controlled, crossover manner, an increase in the &#x003b2;-endorphin plasma level after omeprazole therapy. In contrast to our results, in the study by Tonnarini <italic>et al</italic>.
[<xref ref-type="bibr" rid="CIT0020">20</xref>], 30-day treatment with omeprazole did not influence the plasma level of &#x003b2;-endorphin in patients with duodenal ulcer disease. However, in other studies, the plasma &#x003b2;-endorphin concentration rose in response to hypoglycaemia, intense physical exercise, surgery, and psychological stress in patients with heart failure, as well as during therapy with ketoconazole and naloxone [<xref ref-type="bibr" rid="CIT0014">14</xref>, <xref ref-type="bibr" rid="CIT0022">22</xref>]. Dexamethasone administration decreases this opioid's plasma level. After ketoconazole therapy the &#x003b2;-endorphin level increases fivefold [<xref ref-type="bibr" rid="CIT0014">14</xref>] but, in our study, following omeprazole it increased on average by 2000 times and, after the placebo, by more than 100 times. Because &#x003b2;-endorphins play an endocrine role in brain-gut axis function [<xref ref-type="bibr" rid="CIT0023">23</xref>], among others, as the endogenous analgesia system, these results might explain the improvement in anginal symptoms observed by us in 35% of patients with CAD after 14-day omeprazole administration (&#x0201c;responders&#x0201d;) [<xref ref-type="bibr" rid="CIT0007">7</xref>]. Increase in &#x003b2;-endorphin plasma level after treatment with omeprazole might also elucidate the observation made by Sarkar <italic>et al</italic>. [<xref ref-type="bibr" rid="CIT0024">24</xref>] in patients with chest pain and GORD. They found that 6-week therapy with a proton pump inhibitor increases the resting oesophageal pain threshold via a decrease in central sensitization.</p><p>However, in our investigation responders to the &#x0201c;omeprazole test&#x0201d; had a lower average &#x003b2;-endorphin plasma concentration than subjects who failed to respond to it in one-factorial analysis (<xref ref-type="fig" rid="F0002">Figures 2</xref> and <xref ref-type="fig" rid="F0003">3</xref>). Moreover, the opioid level was higher in patients with greater severity of angina symptoms at the beginning of the study and was not related to the course of the treadmill stress test, including the time to the appearance of chest pain (angina threshold). These observations do not corroborate the above-mentioned hypotheses. They are also not consistent with the results of Tonnarini <italic>et al</italic>. [<xref ref-type="bibr" rid="CIT0020">20</xref>], Falcone <italic>et al</italic>. [<xref ref-type="bibr" rid="CIT0015">15</xref>], and Sadith <italic>et al</italic>. [<xref ref-type="bibr" rid="CIT0018">18</xref>, <xref ref-type="bibr" rid="CIT0019">19</xref>]. The first showed a significantly higher &#x003b2;-endorphin plasma level in patients with an asymptomatic active duodenal ulcer than in subjects with a painful course of disease [<xref ref-type="bibr" rid="CIT0020">20</xref>]. The second found a higher plasma level of &#x003b2;-endorphin in asymptomatic patients with silent ischaemia during exercise stress test than in subjects with anginal symptoms. The third observed that &#x003b2;-endorphin infusion decreased adenosine-provoked chest pain in male patients with CAD, whereas naloxone, an opioid receptor antagonist, induced the opposite effect [<xref ref-type="bibr" rid="CIT0018">18</xref>, <xref ref-type="bibr" rid="CIT0019">19</xref>]. Jarmukli <italic>et al</italic>. [<xref ref-type="bibr" rid="CIT0014">14</xref>], although they showed that an increased &#x003b2;-endorphin plasma concentration augmented the peripheral pain threshold to radiant heat, similarly to our results, do not confirm a significant effect of the &#x003b2;-endorphin level on the angina threshold and workload during an exercise test in patients with stable angina pectoris. The different influence of &#x003b2;-endorphins on somatic and cardiac pain perception was explained by the specific effect of peripheral nociceptors, a distinct central mechanism of somatic and cardiac sensation perception in the thalamus, and a different central and circulating opioid effect [<xref ref-type="bibr" rid="CIT0014">14</xref>, <xref ref-type="bibr" rid="CIT0021">21</xref>]. The last explanation may elucidate improvement only in 35% of subjects observed in our study, although the higher plasma level of &#x003b2;-endorphin in patients who failed to respond to the &#x0201c;omeprazole test&#x0201d; and in patients with greater severity of angina symptoms before involvement in the study is difficult to explain. One of the potential explanations of these observations may be a significantly greater hypertensive response to exercise in non-responders than in responders at the study beginning (systolic blood pressure: 174 &#x000b1;20 vs. 157 &#x000b1;16, <italic>p</italic> = 0.004, and diastolic blood pressure: 98 &#x000b1;11 vs. 91 &#x000b1;8, <italic>p</italic> = 0.04). Ring <italic>et al</italic>. [<xref ref-type="bibr" rid="CIT0021">21</xref>] suggested that hypertension appears to be characterised by greater levels of &#x003b2;-endorphins in the peripheral circulation. The second potential explanation of higher opioid plasma levels in non-responders might be higher anxiety level, secondary to symptoms severity [<xref ref-type="bibr" rid="CIT0014">14</xref>, <xref ref-type="bibr" rid="CIT0022">22</xref>]. Panic disorders are frequent in patients with CAD [<xref ref-type="bibr" rid="CIT0025">25</xref>]. On the other hand, it is proven that pain causes anxiety and panic disorders increase the intensity of pain, thus demanding higher doses of analgesics, in our study endogenous &#x003b2;-endorphins [<xref ref-type="bibr" rid="CIT0026">26</xref>]. Unfortunately, we did not measure anxiety level in our investigation. Thirdly, it may also be supposed that failure of symptoms improvement after treatment with omeprazole resulted from a very low pain threshold in &#x0201c;non-responders&#x0201d;. In this way, the greater &#x003b2;-endorphin plasma level in such patients would be a compensatory reaction, although in our study not sufficient to give pain relief.</p><p>The potential mechanism of increase in the &#x003b2;-endorphin plasma concentration after omeprazole administration may only be supposed. The most probable is acting via the stimulation of pituitary opioid release, similar to ketoconazole [<xref ref-type="bibr" rid="CIT0014">14</xref>]. Neuroendocrine activation associated with stress or anxiety provoked by symptom severity or myocardial ischaemia cannot be excluded [<xref ref-type="bibr" rid="CIT0022">22</xref>], although this hypothesis is not consistent with the lower plasma level of this opioid both at the beginning of the study and following the placebo phase when symptoms severity was greater. An increase in the &#x003b2;-endorphin level after therapy with omeprazole may also be explained by the recently proven anti-inflammatory action of proton pump inhibitors in patients with GORD (a decrease in mucosal IL-8) [<xref ref-type="bibr" rid="CIT0027">27</xref>]. It is known that the administration of proton pump inhibitors diminishes acute inflammatory cell infiltration in oesophageal mucosa. The remaining chronic inflammation dominated by T-lymphocytes is associated with an increase in &#x003b2;-endorphin release and a reduction in visceral pain perception [<xref ref-type="bibr" rid="CIT0028">28</xref>]. This effect, also observed in patients with chronic or quiescent colitis, is explained by feedback neuro-immune cross-talk between mucosal T-cells and the enteric nervous system mediated via &#x003b2;-endorphin [<xref ref-type="bibr" rid="CIT0028">28</xref>, <xref ref-type="bibr" rid="CIT0029">29</xref>]. Moreover, because it is known that omeprazole inhibits cytochrome P450 (CYP) 2C19, its influence on &#x003b2;-endorphin clearance should also be taken into consideration [<xref ref-type="bibr" rid="CIT0030">30</xref>, <xref ref-type="bibr" rid="CIT0031">31</xref>].</p><p>Our investigation has some limitations. Firstly, sample size was limited to 48 patients, although other similar cross-over trials have involved even fewer patients than our study [<xref ref-type="bibr" rid="CIT0005">5</xref>, <xref ref-type="bibr" rid="CIT0006">6</xref>]. Our results, similarly to the cited works, reached statistical significance. On the other hand, together with the relatively small subject sample size the risk of an influence of confounding factors (e.g. pharmacology, age, gender, diabetes mellitus) appears. However, this bias was minimized by the cross-over study design and the use of ANOVA with three repetitions as a statistical method (each patient acted as his or her own control), as well as by subgroup analysis. All these methods decreased the role of sample size and confounding factors, especially differences in kind and dosage of medication. Secondly, in the investigation design we did not provide a &#x0201c;washout period&#x0201d;. This fact may be a cause of the relatively high &#x003b2;-endorphin plasma level after 14 days of placebo administration, in patients who were randomized to taking omeprazole as the first drug. However, the observed changes in &#x003b2;-endorphin plasma level were similar irrespectively of the sequence of treatment (first week omeprazole and then placebo or the other way round). So, the lack of &#x0201c;washout&#x0201d; seems to have no significant effect on the obtained results.</p><p>In conclusion, 14-day therapy with a double dose of omeprazole significantly increases &#x003b2;-endorphin plasma concentration in patients with CAD. Circulating &#x003b2;-endorphin does not seem to be involved in the mechanism for the &#x0201c;omeprazole test&#x0201d; outcome, although an individually different effect on pain threshold cannot be excluded.</p></sec></body><back><ack><title>Acknowledgments</title><p>This investigation was funded by departmental sources from Nicolaus Copernicus University in Toru&#x00144;, and Collegium Medicum in Bydgoszcz. We obtained a free supply of kits of omeprazole and the placebo on the basis of a written contract between POLPHARMA and Collegium Medicum in Bydgoszcz. We would like to express our sincere thanks to Associate Professor Marcin Zi&#x000f3;&#x00142;kowski for his substantial advice. None of the pharmaceutical companies has provided any commercial sources for this study. None of the authors has declared any conflict of interest in accordance with the results of this study.</p><p>In Department of Gastroenterology, Vascular Diseases and Internal Medicine, Nicolaus Copernicus University in Toru&#x00144;, Collegium Medicum in Bydgoszcz the study was performed.</p><p>Conflict of interest: None declared.</p></ack><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fass</surname><given-names>R</given-names></name><name><surname>Navarro-Rodriguez</surname><given-names>T</given-names></name></person-group><article-title>Noncardiac chest pain</article-title><source>J Clin Gastroenterol</source><year>2008</year><volume>42</volume><fpage>636</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">18364579</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickman</surname><given-names>R</given-names></name><name><surname>Fass</surname><given-names>R</given-names></name></person-group><article-title>Noncardiac chest pain</article-title><source>Clin Gastroenterol Hepatol</source><year>2006</year><volume>4</volume><fpage>558</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16630758</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00160;wi&#x00105;tkowski</surname><given-names>M</given-names></name><name><surname>Budzy&#x00144;ski</surname><given-names>J</given-names></name><name><surname>K&#x00142;opocka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease</article-title><source>Med Sci Monit</source><year>2004</year><volume>10</volume><fpage>CR524</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15328486</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flook</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Vakil</surname><given-names>N</given-names></name></person-group><article-title>Approach to gastroesophageal reflux disease in primary care: Putting the Montreal definition into practice</article-title><source>Can Fam Physician</source><year>2008</year><volume>54</volume><fpage>701</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18474703</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickman</surname><given-names>R</given-names></name><name><surname>Emmons</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><etal/></person-group><article-title>The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><fpage>547</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16167971</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname><given-names>J</given-names></name><name><surname>Fullerton</surname><given-names>H</given-names></name><name><surname>Briseno</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Fass</surname><given-names>R</given-names></name></person-group><article-title>The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain-a randomized, double-blind, placebo controlled, crossover trial</article-title><source>Aliment Pharmacol Ther</source><year>2004</year><volume>19</volume><fpage>1123</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15142202</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budzy&#x00144;ski</surname><given-names>J</given-names></name><name><surname>K&#x00142;opocka</surname><given-names>M</given-names></name><name><surname>Pulkowski</surname><given-names>G</given-names></name><etal/></person-group><article-title>The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease &#x02013; a randomised, double-blind, placebo controlled, crossover trial</article-title><source>Int J Cardiol</source><year>2008</year><volume>127</volume><fpage>233</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17689732</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drewes</surname><given-names>AM</given-names></name><name><surname>Arendt-Nielsen</surname><given-names>L</given-names></name><name><surname>Funch-Jensen</surname><given-names>P</given-names></name><name><surname>Gregersen</surname><given-names>H</given-names></name></person-group><article-title>Experimental human pain models in gastro-esophageal reflux disease and unexplained chest pain</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>2806</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16718803</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sifrim</surname><given-names>D</given-names></name><name><surname>Mittal</surname><given-names>R</given-names></name><name><surname>Fass</surname><given-names>R</given-names></name><etal/></person-group><article-title>Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms</article-title><source>Aliment Pharmacol Ther</source><year>2007</year><volume>25</volume><fpage>1003</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">17439501</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>A</given-names></name><name><surname>Petch</surname><given-names>MC</given-names></name><name><surname>Schofield</surname><given-names>PM</given-names></name></person-group><article-title>Cardio-oesophageal reflex in humans as a mechanism for &#x0201c;linked angina&#x0201d;</article-title><source>Eur Heart J</source><year>1996</year><volume>17</volume><fpage>407</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">8737215</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrzycki</surname><given-names>S</given-names></name><name><surname>Baniukiewicz</surname><given-names>A</given-names></name><name><surname>Korecki</surname><given-names>J</given-names></name><etal/></person-group><article-title>Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD?</article-title><source>Int J Cardiol</source><year>2005</year><volume>104</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16137512</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickman</surname><given-names>R</given-names></name><name><surname>Schiff</surname><given-names>E</given-names></name><name><surname>Holland</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn</article-title><source>Aliment Pharmacol Ther</source><year>2007</year><volume>26</volume><fpage>1333</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17875198</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>W</given-names></name><name><surname>Petty</surname><given-names>MA</given-names></name><name><surname>Sitsen</surname><given-names>JM</given-names></name></person-group><article-title>Role of opioid peptides in brain mechanisms regulating blood pressure</article-title><source>Chest</source><year>1983</year><volume>83</volume><fpage>306</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">6295707</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarmukli</surname><given-names>NF</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Iranmanesh</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>DC</given-names></name></person-group><article-title>Effect of raised plasma beta endorphin concentrations on peripheral pain and angina thresholds in patients with stable angina</article-title><source>Heart</source><year>1999</year><volume>82</volume><fpage>204</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10409537</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>C</given-names></name><name><surname>Specchia</surname><given-names>G</given-names></name><name><surname>Rondanelli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Correlation between beta-endorphin plasma levels and anginal symptoms in patients with coronary artery disease</article-title><source>J Am Coll Cardiol</source><year>1988</year><volume>11</volume><fpage>719</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">2965173</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krittayaphong</surname><given-names>R</given-names></name><name><surname>Light</surname><given-names>KC</given-names></name><name><surname>Golden</surname><given-names>RN</given-names></name><name><surname>Finkel</surname><given-names>JB</given-names></name><name><surname>Sheps</surname><given-names>DS</given-names></name></person-group><article-title>Relationship among depression scores, beta-endorphin, and angina pectoris during exercise in patients with coronary artery disease</article-title><source>Clin J Pain</source><year>1996</year><volume>12</volume><fpage>126</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8776552</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Light</surname><given-names>KC</given-names></name><name><surname>Herbst</surname><given-names>MC</given-names></name><name><surname>Bragdon</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Depression and type A behavior pattern in patients with coronary artery disease: relationships to painful versus silent myocardial ischemia and beta-endorphin responses during exercise</article-title><source>Psychosom Med</source><year>1991</year><volume>53</volume><fpage>669</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">1758950</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadigh</surname><given-names>B</given-names></name><name><surname>Berglund</surname><given-names>M</given-names></name><name><surname>Fillingim</surname><given-names>RB</given-names></name><name><surname>Sheps</surname><given-names>D</given-names></name><name><surname>Sylv&#x000e9;n</surname><given-names>C</given-names></name></person-group><article-title>beta-Endorphin modulates adenosine provoked chest pain in men, but not in women-a comparison between patients with ischemic heart disease and healthy volunteers</article-title><source>Clin J Pain</source><year>2007</year><volume>23</volume><fpage>750</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18075400</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadigh-Lindell</surname><given-names>B</given-names></name><name><surname>Sylv&#x000e9;n</surname><given-names>C</given-names></name><name><surname>Berglund</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>BE</given-names></name></person-group><article-title>Role of adenosine and opioid-receptor mechanisms for pain in patients with silent myocardial ischemia or angina pectoris: a double-blind, placebo-controlled study</article-title><source>J Cardiovasc Pharmacol</source><year>2003</year><volume>42</volume><fpage>757</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">14639098</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonnarini</surname><given-names>GF</given-names></name><name><surname>Delle Fave</surname><given-names>G</given-names></name><name><surname>Chianelli</surname><given-names>M</given-names></name><name><surname>Mariani</surname><given-names>P</given-names></name><name><surname>Negri</surname><given-names>M</given-names></name></person-group><article-title>Beta-endorphin in silent duodenal ulcer</article-title><source>Eur J Gastroenterol Hepatol</source><year>1995</year><volume>7</volume><fpage>357</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">7600142</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>C</given-names></name><name><surname>France</surname><given-names>CR</given-names></name><name><surname>al'Absi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of opioid blockade with naltrexone and distraction on cold and ischemic pain in hypertension</article-title><source>J Behav Med</source><year>2007</year><volume>30</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">17205392</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldroyd</surname><given-names>KG</given-names></name><name><surname>Harvey</surname><given-names>K</given-names></name><name><surname>Gray</surname><given-names>CE</given-names></name><name><surname>Beastall</surname><given-names>GH</given-names></name><name><surname>Cobbe</surname><given-names>SM</given-names></name></person-group><article-title>Beta endorphin release in patients after spontaneous and provoked acute myocardial ischaemia</article-title><source>Br Heart J</source><year>1992</year><volume>67</volume><fpage>230</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1313275</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefano</surname><given-names>GB</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Cadet</surname><given-names>P</given-names></name><name><surname>Bilfinger</surname><given-names>TV</given-names></name><name><surname>Mantione</surname><given-names>K</given-names></name></person-group><article-title>Morphine enhances nitric oxide release in the mammalian gastrointestinal tract via the micro(3) opiate receptor subtype: a hormonal role for endogenous morphine</article-title><source>J Physiol Pharmacol</source><year>2004</year><volume>55</volume><fpage>279</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">15082884</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>DG</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name><name><surname>Hobson</surname><given-names>AR</given-names></name><name><surname>Millane</surname><given-names>T</given-names></name><name><surname>Aziz</surname><given-names>Q</given-names></name></person-group><article-title>Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression</article-title><source>Am J Gastroenterol</source><year>2004</year><volume>99</volume><fpage>1998</fpage><lpage>2006</lpage><pub-id pub-id-type="pmid">15447763</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>K</given-names></name><name><surname>Rait</surname><given-names>G</given-names></name><name><surname>Petersen</surname><given-names>I</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Nazareth</surname><given-names>I</given-names></name></person-group><article-title>Panic disorder and risk of new onset coronary heart disease, acute myocardial infarction, and cardiac mortality: cohort study using the general practice research database</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><fpage>2981</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18948354</pub-id></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macha&#x00142;a</surname><given-names>W</given-names></name><name><surname>Rysz</surname><given-names>J</given-names></name><name><surname>Gaszy&#x00144;ski</surname><given-names>T</given-names></name><name><surname>Gaszy&#x00144;ski</surname><given-names>W</given-names></name></person-group><article-title>Analgetic and sedative agents administered to the patients in life-threatening conditions</article-title><source>Arch Med Sci</source><year>2005</year><volume>1</volume><fpage>138</fpage><lpage>43</lpage></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isomoto</surname><given-names>H</given-names></name><name><surname>Nishi</surname><given-names>Y</given-names></name><name><surname>Kanazawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Immune and inflammatory responses in GERD and lansoprazole</article-title><source>J Clin Biochem Nutr</source><year>2007</year><volume>41</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">18193101</pub-id></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma-Gandhu</surname><given-names>M</given-names></name><name><surname>Verdu</surname><given-names>EF</given-names></name><name><surname>Cohen-Lyons</surname><given-names>D</given-names></name><name><surname>Collins</surname><given-names>SM</given-names></name></person-group><article-title>Lymphocyte-mediated regulation of beta-endorphin in the myenteric plexus</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2007</year><volume>292</volume><fpage>G344</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16959949</pub-id></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma-Gandhu</surname><given-names>M</given-names></name><name><surname>Verdu</surname><given-names>EF</given-names></name><name><surname>Bercik</surname><given-names>P</given-names></name><etal/></person-group><article-title>Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse</article-title><source>Gut</source><year>2007</year><volume>56</volume><fpage>358</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">17018864</pub-id></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlos</surname><given-names>MA</given-names></name><name><surname>Du Souich</surname><given-names>P</given-names></name><name><surname>Carlos</surname><given-names>R</given-names></name><name><surname>Suarez</surname><given-names>E</given-names></name><name><surname>Lukas</surname><given-names>JC</given-names></name><name><surname>Calvo</surname><given-names>R</given-names></name></person-group><article-title>Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat</article-title><source>J Pharm Sci</source><year>2002</year><volume>91</volume><fpage>1627</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">12115824</pub-id></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrashekhar</surname><given-names>SM</given-names></name><name><surname>Chakrabarti</surname><given-names>A</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name></person-group><article-title>Pharmacodynamic interactions of omeprazole with CNS active drugs in rats</article-title><source>Indian J Physiol Pharmacol</source><year>1995</year><volume>39</volume><fpage>74</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7705876</pub-id></element-citation></ref></ref-list></back></article>